A controlled trial of terlipressin plus banding ligation versus terlipressin alone in the management of acute esophageal variceal bleeding

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN28353453

Enrollment

120

Registered

2006-03-30

Start date

2005-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute oesophageal variceal bleeding but stopped bleeding during emergency endoscopy Nutritional, Metabolic, Endocrine Oesophageal varices

Interventions

Group 1: terlipressin infusion for five days Group 2: banding ligation performed during emergency endoscopy and terlipressin infusion for two days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cirrhotic patients 2. Acute oesophageal variceal bleeding proven by emergency endoscopy within 12 hours

Exclusion criteria

Exclusion criteria: 1. Association with advanced hepatocellular carcinoma (HCC) 2. Association with other severe systemic illness 3. Association with gastric variceal bleeding 4. Previous shunt operation, endoscopic variceal ligation (EVL), beta-blocker or isosorbide mononitrate (ISMN) within one month 5. Serum bilirubin >10 mg/dl, creatinine >3 mg/dl 6. Presence of encephalopathy >grade 2 6. History of coronary artery disease 7. Uncooperative

Design outcomes

Primary

Measure	Time frame
Initial control of variceal bleeding after 48 hours of treatment	—

Secondary

Measure	Time frame
Early rebleeding between 48-120 hours after treatment	—

Countries

Taiwan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026